Mamta Singh, MD
Geriatric Medicine · Willimantic, CTNPI 1891031522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $474 and has fallen 95.3% since, to $22 in 2024.
Across 49 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$208
- AbbVie$183
- Boehringer Ingelheim$128
- Lilly USA, LLC$91
- Abbott$67
- GSK$66
- plus $223 from 8 others
What the payments were for
- Food & beverage$965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $208 |
| AbbVie | 11 | $183 |
| Boehringer Ingelheim | 5 | $128 |
| Lilly USA, LLC | 4 | $91 |
| Abbott | 4 | $67 |
| GSK | 3 | $66 |
| Arbor Pharmaceuticals, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Pfizer | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| AstraZeneca | 1 | $14 |
How this compares
$965 in reported general payments places this provider in the 85th percentile of 84 geriatric medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $144,436 |
| JardianceEmpagliflozin | 59 | $89,233 |
| JanuviaSitagliptin Phosphate | 60 | $79,930 |
| EliquisApixaban | 40 | $53,994 |
| TrulicityDulaglutide | 35 | $49,647 |
| TradjentaLinagliptin | 20 | $26,258 |
| MounjaroTirzepatide | 19 | $25,179 |
| FarxigaDapagliflozin Propanediol | 22 | $19,718 |
| Fondaparinux Sodium | 11 | $17,232 |
| QuliptaAtogepant | 11 | $13,989 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,644 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,193 |
| Oxcarbazepine | 23 | $3,675 |
| Gabapentin | 174 | $3,472 |
| Atorvastatin Calcium | 414 | $3,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $208 | $144,43684 claims |
| Boehringer IngelheimJardiance, Tradjenta | $128 | $115,49179 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $91 | $74,82654 claims |
| PfizerEliquis | $20 | $53,99440 claims |
| AstraZenecaFarxiga | $14 | $19,71822 claims |
| AbbVieQulipta | $183 | $13,98911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 84 geriatric medicine providers in Connecticut.
Other geriatric medicine in Willimantic
- Margarita ReyesBristol$67K
- Susann VaranoNew Haven$25K
- Imran AliBridgeport$13K
- Sowmya KurtakotiHartford$9K
- Maria RennaWethersfield$6K
- Henry YaggiNew Haven$5K
- Marina BlagodatnyStratford$3K
- Jessica DacostaBrookfield$2K
- George KuchelFarmington$1K
- Edward BermanRidgefield$939
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.